Laverdia is a drug owned by DECHRA, LTD. It is protected by 7 US drug patents filed in 2032. All patents are active. Details of Laverdia’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US9714226 | 26 Jul, 2032 | Active |
| US9079865 | 26 Jul, 2032 | Active |
| US10173987 | 26 Jul, 2032 | Active |
| US9206158 | 26 Jul, 2032 | Active |
| US10544108 | 26 Jul, 2032 | Active |
Exclusivity Information
Laverdia holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Laverdia's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Dec 18, 2030 |
About Laverdia
Laverdia is a drug
owned by DECHRA, LTD.
Laverdia uses
Verdinexor as the active
ingredient.
Active Ingredient:
Laverdia uses
Verdinexor as the active ingredient.
Check out other Drugs and Companies using
Verdinexor ingredient.